Page 14 - Gamida Cell News Today

Shares of Gamida Cell Ltd. (NASDAQ:GMDA – Get Rating) have been assigned an average rating of “Buy” from the seven analysts that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year price […]

Gamida Cell (NASDAQ:GMDA – Get Rating)‘s stock had its “buy” rating reaffirmed by stock analysts at JMP Securities in a note issued to investors on Thursday, TipRanks reports. They presently have a $17.00 price objective on the stock. A number of other equities analysts have also weighed in on GMDA. Zacks Investment Research lowered shares […]

Gamida Cell Ltd. (NASDAQ:GMDA – Get Rating) was the recipient of a large decline in short interest in May. As of May 15th, there was short interest totalling 3,040,000 shares, a decline of 16.3% from the April 30th total of 3,630,000 shares. Currently, 7.3% of the company’s stock are sold short. Based on an average […]

Analysts predict that Gamida Cell Ltd. (NASDAQ:GMDA – Get Rating) will report earnings of ($0.31) per share for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for Gamida Cell’s earnings, with estimates ranging from ($0.32) to ($0.29). Gamida Cell posted earnings per share of ($0.42) during the same quarter last year, which […]

Gamida Cell Ltd. (NASDAQ:NASDAQ:GMDA) Q1 2022 Results Conference Call May 10, 2022 08:00 AM ET Company Participants Heather DiVecchia - Chief of Staff Michele Korfin - Chief Operating...

GMDA earnings call for the period ending March 31, 2022.

(2022-05-05 | NDAQ:ORGO) Organogenesis Appoints Michele Korfin and Gilberto Quintero, Ph.D. to Board of Directors

GDA-201 is an off-the-shelf cell therapy candidate for the treatment of patients with follicular and diffuse large B cell lymphomas.

Equities research analysts expect that Gamida Cell Ltd. (NASDAQ:GMDA – Get Rating) will post earnings of ($0.34) per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Gamida Cell’s earnings, with the highest EPS estimate coming in at ($0.30) and the lowest estimate coming in at ($0.38). Gamida Cell also […]

Gamida Cell (NASDAQ:GMDA – Get Rating) and Passage Bio (NASDAQ:PASG – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, dividends, analyst recommendations, institutional ownership and profitability. Insider and Institutional Ownership 53.4% of Gamida Cell shares […]